Research location
Burton-on-Trent
United Kingdom
Advertisement
Research activity in Burton-on-Trent
United KingdomCureCurrent currently publishes aggregate city-level research activity for this location: 15 trials and 15 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Burton-on-Trent
15 linked trials · page 1 of 1A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)NCT05085028 · 2022-06-23 · 1 site observation
RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Prehabilitation and RecOVERy From Surgery for Breast Cancer StudyNCT05901142 · 2023-06-16 · 1 site observation
UNKNOWN
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)NCT02585778 · 2015-10-23 · 1 site observation
COMPLETED
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot UlcersNCT02447172 · 2015-06-01 · 1 site observation
COMPLETED
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney DiseaseNCT02358096 · 2015-03-17 · 1 site observation
COMPLETED
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic AgentNCT02046603 · 2014-03-04 · 1 site observation
COMPLETED
Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)NCT01788332 · 2014-01-01 · 1 site observation
UNKNOWN
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)NCT01562028 · 2012-06-01 · 1 site observation
COMPLETED
A Randomised Trial of Pulmonary Metastasectomy in Colorectal CancerNCT01106261 · 2010-12-02 · 1 site observation
COMPLETED
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast CancerNCT00820222 · 2009-04-14 · 1 site observation
COMPLETED
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) TherapyNCT00883753 · 2009-03-01 · 1 site observation
COMPLETED
A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIALNCT00801853 · 2009-03-01 · 1 site observation
COMPLETED
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.NCT00750880 · 2008-09-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.